There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CEACAM-1


CEACAM-1 Molecule Information

Name:Carcinoembryonic antigen related cell adhesion molecule 1
Target Synonym:CEACAM1,Biliary glycoprotein 1,BGP,CD66a,Carcinoembryonic Antigen Related Cell Adhesion Molecule 1,CD66a Antigen,BGP1,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1,Antigen CD66,BGP-1,BGPI,CEA Cell Adhesion Molecule 1,Carcinoembryonic Antigen-R
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:0
Lastest Research Phase:Phase 2 Clinical

CEACAM-1 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
CE1-H82E5 Human Biotinylated Human CEACAM-1 / CD66a Protein, Avitag™,His Tag
CE1-H5220 Human Human CEACAM-1 / CD66a Protein, His Tag

CEACAM-1 Part of Bioactivity data

Human CEACAM-1, His TagHuman CEACAM-1, His Tag (Cat. No. CE1-H5220) ELISA bioactivity

Immobilized Human CEACAM-1, His Tag (Cat. No. CE1-H5220) at 10 μg/mL (100 μL/well) can bind Biotinylated Human CEACAM-8, His,Avitag (Cat. No. CE8-H82E9) with a linear range of 0.039-1.25 μg/mL (QC tested).

Biotinylated Human CEACAM-1, Avitag,His TagBiotinylated Human CEACAM-1, Avitag,His Tag (Cat. No. CE1-H82E5) ELISA bioactivity

Immobilized Human CD209, His Tag (Cat. No. CD9-H5246) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CEACAM-1, Avitag,His Tag (Cat. No. CE1-H82E5) with a linear range of 10-78 ng/mL (QC tested).

CEACAM-1 Molecule Synonym Name


CEACAM-1 Molecule Background

Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is also known as Biliary glycoprotein 1 (BGP1), CD66a, which belongs to the immunoglobulin superfamily or CEA family. CEACAM1 /CD66a contains three Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. CEACAM1 /CD66a was described as an adhesion molecule mediating cell adhesion via both homophilic and heterophilic manners, and was detected on leukocytes, epithelia, and endothelia. Studies have revealed that CEACAM1 / BGP-1 performs actions in multiple cellular processes including tissue differentiation, angiogenesis, apoptosis, metastasis, as well as the modulation of innate and adaptive immune responses.

CEACAM-1 References

CEACAM-1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CM-24 CM-24; MK-6018 Phase 2 Clinical Merck Sharp & Dohme Corp Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Thyroid Cancer, Papillary; Carcinoma, Non-Small-Cell Lung; Melanoma Details

This web search service is supported by Google Inc.